Currently out of the existing stock ratings of Michael Ryskin, 13 are a HOLD (28.26%), 23 are a BUY (50%), 10 are a SELL (21.74%).

Michael Ryskin

Work Performance Price Targets & Ratings Chart

Analyst Michael Ryskin works at BAML with a stock forecast success ratio of 72.02% fulfilled within 135.21 days on average.

Michael Ryskin’s has documented 90 price targets and ratings displayed on 14 stocks. The coverage is on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on MRVI, Maravai Lifesciences Holdings  at 12-Dec-2023.

Wall Street Analyst Michael Ryskin

Analyst best performing recommendations are on OMIC (SINGULAR GENOMICS SYSTEMS).
The best stock recommendation documented was for OMIC (SINGULAR GENOMICS SYSTEMS) at 6/21/2021. The price target of $26 was fulfilled within 3 days with a profit of $2.84 (12.26%) receiving and performance score of 40.88.

Average potential price target upside

ABSI Absci Corp ALGN Align Technology ELAN Elanco Animal Health IDXX IDEXX Laboratories OMIC Singular Genomics Systems SDC SmileDirectClub SDGR Schrodinger RXRX Recursion Pharmaceuticals EXAI Exscientia Ltd ADR ZTS Zoetis MRVI Maravai Lifesciences Holdings  ILMN Illumina AVTR Avantor CERT Certara

Analyst name


Current price target

Potential distance

Previous price target


Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score



$2.32 (49.57%)


1 months 18 days ago

3/4 (75%)

$3.38 (93.37%)




9 months 10 days ago

0/3 (0%)

$9.22 (192.89%)



$5.32 (113.68%)


1 years 8 months 26 days ago

0/2 (0%)

$6.35 (173.97%)



$8.68 (657.58%)

2 years 3 months 15 days ago

1/1 (100%)

$-2.96 (-22.84%)




$25.32 (541.03%)

2 years 6 months 10 days ago

0/1 (0%)

$8.91 (42.25%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Michael Ryskin is most bullish on?

Potential upside of $1.64 has been obtained for MRVI (MARAVAI LIFESCIENCES HOLDINGS )

What Year was the first public recommendation made by Michael Ryskin?

On 2017

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?